It’s personal

Improving the lives of patients is a personal matter for each and every member of our team at Protagen. You’ll see this in the passion we apply to the discovery, identification, and validation of novel biomarker panels for better diagnostic (Dx) and companion diagnostic (CDx) tests. It is demonstrated by the commitment and expertise we bring to our partnerships when working on clinical development programs. Our dedication to advancing diagnostics for personalized medicine is evident in everything we do.

Diagnostics Differentiated

We are adding a new dimension to the world of diagnostics. Our SeroTag biomarker development engine delivers unique biomarker signatures. The disease-specific signatures that we identify, often based on novel markers, are the basis for new diagnostic strategies that will improve the differentiation and stratification of patients. The result is a new medical scenario in which disease states are recognized earlier, and medical care can be more specifically and effectively provided.

Learn more

News

Protagen AG Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that Dr. Oliver Schacht, CEO of Curetis N.V., Holzgerlingen, has joined the company's Supervisory Board. Additionally, Dr. Bernhard Kirschbaum, former Merck Pharma Executive and member of the Protagen Board since 2015, was elected as the new Chairman, taking over the position from Prof. Dr. Axel Kleemann.

Protagen announces CE Mark for its proprietary Multilisa® BICD2 test for better diagnosis of Systemic Sclerosis

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced that it gained CE marking for the Multilisa® BICD2 test. BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).

Protagen launches first CE marked diagnostic assays Multilisa CENP-B and Scl-70 for the diagnosis of Systemic Sclerosis

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced the launch of its first CE marked diagnostic assays Multilisa® CENP-B and Multilisa® Scl-70 ELISA to aid in the diagnosis of Systemic Sclerosis (SSc).